finanzen.net
12.02.2019 02:05
Bewerten
(0)

The conjunctivitis therapeutics market will register a CAGR of over 8% by 2023

DRUCKEN

NEW YORK, Feb. 11, 2019 /PRNewswire/ -- About this market
Conjunctivitis is inflammation in the inside of the eyelids and the covering of the white of the eye, which causes the conjunctival blood vessels to dilate. While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate. The ease of availability of antibiotic eye drops and ointments for the treatment of bacterial conjunctivitis and antibiotics for viral conjunctivitis is leading to an increase in the use of these therapeutics. The use of therapeutics is primarily to avoid the progression of the disease into severe indications, which could increase the economic burden of patients. Hence, the infectious nature of the disease is expected to increase the adoption rate of therapeutics, thus resulting in the growth of the market during the forecast period. Technavio's analysts have predicted that the conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.

Read the full report: https://www.reportlinker.com/p05734247

Market Overview
Growing allergy cases
Allergic conjunctivitis is caused by various types of allergies such as hay fever and asthma. Being allergic to substances such as dust mites and mold can also increase the risk of infection. Globally. the prevalence of various types of allergies has been growing at a significant rate. The increasing prevalence of allergies such as dust mite allergy and pollen allergy increase the risk of allergic conjunctivitis.
Patent cliff
One of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market. Patent expiration leads to the increasing launch of generic drugs, thereby leading to value erosion of the global market. The patent expiry of blockbuster drugs also impacts the sales of the vendors significantly, making it difficult for vendors to compete in the market. Thus, the patent expiry of blockbuster drugs and the subsequent entry of generics restrict market growth.
For the detailed list of factors that will drive and challenge the growth of the conjunctivitis therapeutics market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Read the full report: https://www.reportlinker.com/p05734247

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-conjunctivitis-therapeutics-market-will-register-a-cagr-of-over-8-by-2023-300793243.html

SOURCE Reportlinker

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht stark ins Wochenende -- Dow Jones weit im Plus -- Allianz verdient mehr -- EZB senkt Eigenkapitalanforderungen für Commerzbank -- Scout24: Neues Übernahmeangebot -- EDF, Zalando im Fokus

Vapiano enttäuscht mit Umsatz und Ergebnis. Warren Buffetts Depot: Apple-Aktien verkauft. TUI-Chef Joussen kauft für fast 1 Million Euro TUI-Aktien. NVIDIA-Gewinn halbiert - Anleger aber zufrieden. Regierungskrise in Spanien. Applied Materials enttäuscht Anleger mit Umsatzausblick. Möglicherweise Milliarden-Bußgeld gegen Facebook in USA.

Die 5 beliebtesten Top-Rankings

Die korruptesten Länder der Welt
In diesen Staaten ist die Korruption am höchsten
Die beliebtesten Marken im Social Web 2018
Kundenlieblinge 2018
Die teuersten Scheidungen
Diesen Menschen kommt das Liebes-Aus teuer zu stehen
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
So viel verdienen die reichsten Amerikaner pro Stunde
Wer ist an der Spitze?
mehr Top Rankings

Umfrage

Sind Sie in Cannabis-Aktien investiert?

finanzen.net Brokerage

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Ceconomy St.725750
Wirecard AG747206
Daimler AG710000
Scout24 AGA12DM8
Apple Inc.865985
Amazon906866
Allianz840400
TeslaA1CX3T
CommerzbankCBK100
E.ON SEENAG99
BASFBASF11
BMW AG519000
Deutsche Telekom AG555750
adidasA1EWWW